This article is more than 5 years old. Information may no longer be current.

PRECISE

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Randomized Clinical Trial of Adipose-Derived Stem Cells in Treatment of Non Revascularizable Ischemic Myocardium

Trial evaluated the safety and feasibility of transendocardial injections of adipose-derived stem and regenerative cells in patients with chronic ischemic HF who were not eligible for percutaneous or surgical revascularization.

Design: randomized, double blind, placebo-controlled
Patients: 26
Centers: multicenter
Countries: Spain, Netherlands, Denmark

Results: Treatment group patients had an improved infarct size (22.1% vs. 28.9%; P=.04), but lower left ventricular ejection fraction (45% vs. 48%) at 6 months compared with placebo. At 18 months, metabolic equivalents (P=.03) and peak oxygen consumption (P=.03) were improved in the treatment group. Additionally, safety data were similar between the two groups.

Presented at: The Sixth International Conference on Cell Therapy for Cardiovascular Disease